This study is looking at whether xylitol, a sugar alcohol, can help clear *Clostridioides difficile* (C. difficile) bacteria from the gut in people with Inflammatory Bowel Disease (IBD). Xylitol is already approved as a food additive. You might be able to join if you are 18 or older, have an IBD diagnosis (Crohn's disease, ulcerative colitis, or indeterminate colitis) that is inactive or mild, and are scheduled for an outpatient colonoscopy or clinic appointment. The study will compare two different doses of xylitol to a placebo (an inactive substance) to see if xylitol can successfully clear C. difficile after 8 weeks, and to check for any side effects. The study aims to enroll 99 participants.

Study design

This is a randomized, placebo-controlled study involving 99 participants. Participants will be assigned by chance to receive one of two doses of xylitol or a placebo, and neither you nor the study team will know which treatment you are receiving.

What's involved

You would take capsules daily for 4 weeks. You will also have C. difficile and microbiome tests at the beginning, at 4 weeks, 8 weeks, 26 weeks, and 52 weeks.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for 52 weeks after starting the treatment, even though dosing stops at week 4.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.